The strengths of this study include the simultaneous assessment of multiple inflammatory biomarkers, the stratification of both T1D and T2D participants by glycemic control, and the use of Tobit regression to account for censoring at the lower detection limit of IL-6. The gene discussed is IL6; the disease is type 2 diabetes mellitus.